Hormonal inhibition of the endometrium for resectoscopic endometrial ablation

Resectoscopic Surgery Part I: Overcoming Obstacles and Mastering the Basics

The introduction of the continuous flow gynecologic resectoscope (CFGR) in 1989 revolutionized minimally invasive gynecologic surgery (MIGS) by introducing such intrauterine procedures as hysteroscopic myomectomy, polypectomy, and endometrial ablation. However, with the subsequent introduction of global endometrial ablation (GEA) devices and hysteroscopic morcellators (HMs), the CFGR has fallen into relative disuse-a regrettable situation since it remains ideally suited for accomplishing many procedures that are otherwise not achievable with these newer technologies. Procedures which involve greater precision and control-endomyometrial resection (EMR), hysteroscopic metroplasty, the correction of isthmoceles, the resection of intramural myomas, and the management of late-onset endometrial ablation failure-are only possible with the CFGR. In addition, the CFGR permits a variety of functions that would otherwise require several different disposable platforms. Despite the benefits of the gynecologic resectoscope, there are clear impediments to its use including a scarcity of educational resources and trained experts, medico-legal concerns, institutional obstacles to organizing an operative team, and the need to develop and maintain an adequate caseload. In Part I of this three-part series, the author will review why the CFGR remains a relevant and indispensable tool for the minimally invasive gynecologic surgeon, the composition of an operating room team, and the instrumentation and skills necessary to accomplish basic resectoscopic surgery. In Part II, we will describe how ultrasound guidance can be used to assist the execution of more challenging intermediate-level cases. Finally, in Part III, we will discuss the most demanding cases for the resectoscopic surgeon-the treatment of post-ablation failures and the removal of intramural leiomyomas-which are clinical scenarios that require ultrasound guidance and well-honed resectoscopic surgical skills.

Endometrial preparation with desogestrel before Essure hysteroscopic sterilization: preliminary study

STUDY OBJECTIVE

To assess the effect of desogestrel on endometrial preparation for transcervical sterilization using the Essure device.

DESIGN

Prospective nonrandomized clinical study (Canadian Task Force classification II-3).

SETTING

Acute-care university-affiliated hospital in Barcelona, Spain.

PATIENTS

Women undergoing sterilization using the Essure device between January 2010 and January 2011.

INTERVENTIONS

Participants were offered desogestrel, 75 μg/d, for 6 weeks before the procedure. Sixteen who accepted were included in the desogestrel group, and 18 who refused were allocated to the no-treatment group. Endometrial biopsy samples were also obtained.

MEASUREMENTS AND MAIN RESULTS

In women who received desogestrel, decidual transformation was observed in eight, glandular atrophy in three, and proliferative endometrium in five. In the no-treatment group, two women had menstruation, nine had proliferative endometrium, and seven had secretory endometrium. In the desogestrel group, the procedure was successful in all women. In the no-treatment group, the procedure was cancelled in two women because of menstruation and in four women with secretory endometrium in whom the tubal ostia were difficult to visualize because of endometrial thickness and bleeding. The median (interquartile range, 25th-75th percentile) duration of the procedure was shorter in the desogestrel group than in the no-treatment group (7 [6-7] minutes vs 8 [7-12] minutes; p = .002).

CONCLUSION

Desogestrel, 75 μg/d, could be an alternative to combined hormonal contraception before placement of Essure inserts, facilitating the procedure and serving as a contraceptive method during the following 12 weeks until occlusion of the tubes.

The practicability and surgeons' subjective experiences with vaginal danazol before an operative hysteroscopy

This randomized, double blind, placebo-controlled study compared the usefulness of danazol 400mg vaginally versus 600mg orally in women as a preoperative preparation for hysteroscopic surgery. Ninety-one fertile women were randomly allocated to Group A (46 patients received 400mg of danazol placed into the posterior vaginal fornix and three oral tablets of commercially available folic acid as a placebo), and Group B [45 women treated with 600mg of danazol orally (200mg three times daily) and two vaginal tablets of Lactobacillus rhamnosus as a placebo]. The patients underwent an operative hysteroscopy, transvaginal sonography, blood tests, and a histological assay. A visual analog scale (VAS) score to compute the degree of the surgeon's satisfaction was used. The outcome measures were as follows: an evaluation of the changes in the endometrial thickness, the prevalence of endometrial atrophy, changes in the blood tests, any collateral effects, the degree of difficulty and view, the duration of the surgical procedure, any complications during the operative hysteroscopy and associated side effects, and the surgeon's satisfaction with the endometrial preparation. The vaginal administration route was associated with a more pronounced effect on the endometrial thickness. Significantly more patients receiving vaginal danazol (45/46) had a hypotrophic endometrium than those receiving oral danazol (37/45, P<0.01). In addition, the patients receiving danazol vaginally had a shorter operating time, lower infusion volume, fewer side effects, and a higher surgeon satisfaction. Vaginal danazol adequately prepares the endometrium for an operative hysteroscopy by thinning the endometrium effectively with few side effects and little impact on the metabolic parameters.

Hysteroscopic surgery: possibilities, limitations and future

With hysteroscopic surgery, specific endoscopic approaches can be applied in selected cases avoiding the need for classical open surgery or even hysterectomy. The development of these surgical procedures has resulted in an increasing interest in the use of diagnostic hysteroscopy in order to identify that intrauterine pathology which is suitable for endoscopic treatment.

Oral contraceptives maintain a very thin endometrium before operative hysteroscopy

OBJECTIVE

To show that early follicular-phase administration of an oral contraceptive pill (OC) consistently provides a thin endometrium, as determined by transvaginal ultrasound. This is an ideal condition when performing operative hysteroscopy.

DESIGN

Retrospective chart review of patients who have undergone ultrasound evaluation of the endometrial thickness under different hormonal conditions. Endometrial measurement was obtained during menstruation, in the late follicular phase, and in the luteal phase in 20 patients. In another group of 100 patients, endometrial measurement was made on the 18th day of OC administration, initiated during menses.

SETTING

A reproductive endocrinology unit in a university-affiliated medical center.

PATIENT(S)

Patients undergoing treatment for subfertility of various etiologies.

INTERVENTION(S)

Transvaginal ultrasound measurements of the endometrium.

MAIN OUTCOME MEASURE(S)

Endometrial thickness by transvaginal ultrasound.

RESULT(S)

Combination OCs started on menstrual days 1-3 maintain a uniformly thin endometrium, 4.1 +/- 1.6 mm (mean +/- SD), comparable to menstrual endometrium (3.7 +/- 1.5 mm). This was statistically thinner compared with endometrium observed in the late follicular phase (11 +/- 2.0 mm) or late luteal phase (12 +/- 2.3 mm). Transvaginal ultrasound measurements of the endometrium under different conditions were compared by the unpaired t-test.

CONCLUSION(S)

Oral contraceptives maintain a very thin, flat endometrium, such that lesions might be readily identified and treated during operative hysteroscopy procedures. Prevention of pregnancy and endometrial thinning with administration of OCs facilitates procedural scheduling for patients and surgeons.

Hysteroscopic and nonhysteroscopic endometrial ablation

Endometrial ablation is defined as the elimination of the endometrium by thermal energy or resection. It was introduced in the 1980s as an alternative to hysterectomy to those patients with abnormal uterine bleeding and benign pathology who are unable or unwilling to tolerate traditional therapies. This article explores various endometrial ablation techniques.

Hysteroscopic myomectomy

Hysteroscopic myomectomy is a minimally invasive technique that eliminates the need for a laparotomy and is associated with lower morbidity than abdominal myomectomy. Its beneficial effects are reflected by the improvement in menstrual pattern, fertility rate, and overall patient satisfaction. It is usually performed as outpatient surgery but occasionally requires an overnight stay. Most patients return to full activity within 48 hours. To exploit the full potentials of this procedure, appropriate case selection and surgical expertise are essential. It should be considered as first-line conservative surgical therapy for the management of symptomatic intracavitary fibroids.

The HydroThermAblator System for Management of Menorrhagia in Women with Submucous Myomas: 12- to 20-Month Follow-up

STUDY OBJECTIVE

To assess the safety and efficacy of the HydroThermAblator (HTA) system to treat patients with menorrhagia and submucous myomas up to 4 cm in diameter.

DESIGN

Retrospective, multicenter, cohort study (Canadian Task Force classification II-2).

SETTING

Two medical centers from a large, prepaid, multispecialty health maintenance organization.

PATIENTS

Twenty-two women.

INTERVENTION

HTA endometrial ablation.

MEASUREMENTS AND MAIN RESULTS

The HTA circulates free-flowing, heated (90 degrees C) saline in the uterine cavity for 10 minutes under direct hysteroscopic control. All procedures were performed in the office under local anesthesia after premedication with oral anxiolytic and analgesic agents. At least 1 year after treatment (average follow-up 15.4 mo, range 12-20 mo), women were contacted regarding their menstrual history. Success was defined as no additional medical or surgical intervention. Amenorrhea was defined as no bleeding, eumenorrhea as normal periods, and oligomenorrhea as less than a normal period. Twelve patients (54%) reported complete amenorrhea; 7 were premenopausal (41% amenorrhea rate) and 5 were postmenopausal (100% amenorrhea rate). Five (23%) reported oligomenorrhea and three (14%) eumenorrhea, and were very satisfied with the result. The overall success rate was 91%. Of two failures (9%), one woman had a repeat HTA 13 months later for menorrhagia. The other had a repeat HTA for persistent spotting and sustained a false passage and small perforation before the procedure began. She elected to have a vaginal hysterectomy 1 month later. Although the results are not statistically significant, patients were extremely satisfied with the outcomes, and no serious complications were related to the device or its use for this indication.

CONCLUSION

HTA is probably safe and effective in treating women with menorrhagia and submucous myomas up to 4 cm in diameter. It offers advantages over hysterectomy and electrosurgical resection since it is an office-based procedure, and significant advantages over other global ablation technologies that, by their design, are unable to treat significantly distorted uterine cavities.

A randomized trial of danazol pretreatment prior to endometrial resection

OBJECTIVES

To assess the effect of danazol pretreatment in women undergoing endometrial resection for dysfunctional uterine bleeding.

STUDY DESIGN

A total of 132 patients were randomly divided into danazol pretreated and untreated groups. Endometrial resection was carried out using a 24Fr cutting wire loop electrode and 1.5% glycine as the distension media. Patients were followed-up for 6 years. The t-test and Chi-square tests were used to test differences between the two groups.

RESULTS

The mean endometrial thickness, fluid used, fluid deficit, weight of resected tissue and duration of surgery were significantly greater in the unprepared group. Over 70% of patients in both the groups achieved amenorrhoea or spotting. Two (1.5%) patients underwent a repeat procedure and two (1.5%) others a hysterectomy, while the rest had hypomenorrhoea. The perimenstrual symptoms also showed significant improvement. No statistically significant difference was found in the outcomes of the two groups.

CONCLUSION

Endometrial resection is an effective alternative to hysterectomy and pretreatment of the endometrium is not necessary for good outcomes.

Hysteroscopic treatment of intrauterine lesions in premenopausal and postmenopausal women

STUDY OBJECTIVE

To compare the safety and efficacy of hysteroscopic surgery in the management of intrauterine lesions in premenopausal and postmenopausal women and, in particular, to investigate whether glycine absorption is different between these populations.

DESIGN

Comparative study (Canadian Task Force classification II-2).

SETTING

Tertiary care university hospital.

PATIENTS

Thirty postmenopausal and 78 premenopausal women with intrauterine polyps or myomas.

INTERVENTION

Hysteroscopic myomectomy or polypectomy.

MEASUREMENTS AND MAIN RESULTS

One hundred eight procedures were completed successfully by hysteroscopy; in two cases myomectomy was completed in a second operation for a deeply embedded myoma. No major complications occurred in either group. Median operating time, mean glycine absorption, and median postoperative hospital stay were not significantly different between groups. During mean follow-up of 15 months (range 1-39 mo), four women underwent hysterectomy (1 for endometrial cancer, 1 for complex hyperplasia with atypia, 2 for pelvic pain and menorrhagia).

CONCLUSION

Hysteroscopic surgery is an effective and safe therapeutic option for intrauterine lesions regardless of a woman's menopausal status.

Is endometrial pre-treatment of value in improving the outcome of transcervical resection of the endometrium?

The aim of this study was to determine whether or not the use of medical pre-treatment of the endometrium improves the outcome of transcervical resection of the endometrium with regards to long-term operative outcome, histological findings and patient satisfaction. A prospective randomized trial comparing three endometrial pre-treatment agents (danazol, medroxyprogesterone acetate or nafarelin) with no pre-treatment was conducted. The main outcome measures were: (i) thickness of the endometrium and myometrium resected; (ii) histological stage of the endometrium at the time of operation; (iii) the presence or absence of menses and (iv) patient satisfaction 1 year post-operatively. Of the three pre-treatments studied, danazol produced a lower median endometrial thickness than the control, showed the greatest ability to induce atrophy of the endometrial glands and stroma (not statistically significant) and produced the highest rate of amenorrhoea (not different to the control). Danazol and nafarelin produced significantly lower median endometrial thickness than no pre-treatment. There were, however, no significant differences in the rates of amenorrhoea in any of the pre-treatment groups compared with that in the control group. No improvement in clinical outcome or patient satisfaction is conferred by the use of medical pre-treatments if transcervical resection of the endometrium is performed in the proliferative phase of the menstrual cycle.

GLOBAL ENDOMETRIAL ABLATION

Hysteroscopic endometrial ablation was introduced in the 1980's as an alternative to hysterectomy in women who failed medical management. Global endometrial ablation was introduced in the 1990's as an easier, safe, and equally effective alternative to hysteroscopic ablation. Several devices have been introduced, some of which are still undergoing feasibility studies or clinical trials. These devices include: three hot water intrauterine balloons, two intrauterine free saline solutions, a multielectrode electrocoagulating balloon, a 3-D bipolar electrocoagulation probe, a microwave, a diode fibre laser, and at least three cryoprobes. These devices require less operator skill and no irrigant or distending solutions. All require either heat or cold to destroy the endometrium. Although all devices are promising and have produced impressive preliminary results, the long-term efficacy, complication rates, and cost effectiveness have not been established. This review describes all devices as they appeared chronologically and presents only peer-reviewed data.

Pathophysiology of abnormal uterine bleeding

Abnormal uterine bleeding is a frequent patient complaint. Recognition of the severity of the problem, appropriate and timely evaluation, and treatment with good outcomes is the goal. The physician must determine which method of diagnosis he or she is most comfortable with, carefully consider the economic impact, and offer treatment that is best suited for each patient. With this practice patients will obtain maximum benefit from the newer treatments in development.

Treatment of the patient without intracavitary pathology. Comparison of traditional hysteroscopic techniques for endometrial ablation

Endometrial ablation has become a necessary and useful procedure for the management of abnormal uterine bleeding in women desiring uterine conservation. Current ablation techniques are safer and more effective than earlier methods. This article explains the steps to perform laser and resectoscopic endometrial ablation and provides suggestions for making these processes more effective.

The septate uterus: a review of management and reproductive outcome

OBJECTIVE

To review the literature on the diagnosis, prevalence, and treatment of the septate uterus, with special reference to hysteroscopic metroplasty and its effect on reproductive outcome.

DESIGN

Pertinent studies were identified through a computer MEDLINE search. References of selected articles were hand-searched for additional citations.

RESULT(S)

Reliable diagnosis of the septate uterus depends on accurate assessment of the uterine fundal contour. At present, the combined use of laparoscopy and hysteroscopy is the gold standard for diagnosis, although recent reports of two-dimensional, transvaginal, contrast ultrasound and of three-dimensional ultrasound appear promising. The prevalence of the septate uterus is increased in women with repeated pregnancy loss. A metaanalysis of published retrospective data comparing pregnancy outcome before and after hysteroscopic septoplasty indicated a marked improvement after surgery.

CONCLUSION(S)

The hysteroscopic approach to treatment, with its simplicity, minimal postoperative sequelae, and improved reproductive outcome, has enabled a more liberalized approach to treatment that is now being extended to include not only patients with recurrent pregnancy loss and premature labor but also patients with infertility, especially if IVF is being contemplated.

Long term follow up of hysteroscopic myomectomy assessed by survival analysis

OBJECTIVE

To identify patient characteristics which affect outcome after hysteroscopic myomectomy for submucous fibroids.

DESIGN

Prospective observational study.

SETTING

A university teaching hospital.

SAMPLE

One hundred and twenty-two consecutive patients treated by hysteroscopic myomectomy for submucous leiomyoma over a period of almost eight years.

METHODS

Hysteroscopic electroresection of the leiomyoama using a continuous flow resectoscope.

MAIN OUTCOME MEASURES

The avoidance of further surgery and patient satisfaction.

RESULTS

The average age of the patients at the time of their surgery was 42.8 years. A total of 194 fibroids were removed. The mean follow up period was 2.3 years (range 1-7.6). Of those asked, 71.4% were satisfied with the results of surgery. Sixteen women required further surgery for fibroids, and six ultimately underwent hysterectomy. Survival analysis showed that the risk of further surgery was 21% at four years after the myomectomy, and 0% thereafter. Univariate regression analysis suggested that outcome was significantly better in older women, and in cases where the uterus was equivalent in size to < or = 6 weeks of gestation, the fibroid was < or = 3 cm in diameter and mainly intra-cavitary, and the procedure time was < or = 20 minutes. The influence of hormonal pre-treatment and the number of fibroids excised was not statistically significant. After multivariate regression analysis, only overall uterine size and the position of the fibroid being removed were found to significantly influence the success of surgery.

CONCLUSIONS

Hysteroscopic myomectomy is an effective way to manage patients with symptomatic submucous leiomyomata, particularly when the uterus is not grossly enlarged and the fibroid(s) are mainly inside the uterine cavity.

Altered uterine artery blood flow impedance after danazol therapy: possible mode of action in dysfunctional uterine bleeding

OBJECTIVE

To test the hypothesis that danazol increases the impedance to uterine circulation and hence reduces the effective uterine blood flow after a predetermined period of therapy.

DESIGN

Prospective, longitudinal study.

SETTING

Reproductive medicine unit of a university teaching hospital.

PATIENT(S)

Eight premenopausal women with dysfunctional uterine bleeding.

INTERVENTION(S)

Six weeks of danazol therapy.

MAIN OUTCOME MEASURE(S)

The uterine artery blood flow impedance as indicated by the pulsatility and resistance indices; the hormonal profile (E2, FSH, and LH levels); the uterine dimensions (length, width, anteroposterior diameter, and area); and the endometrial thickness.

RESULT(S)

The indices of uterine artery impedance were significantly increased after danazol therapy, indicating a possible reduction in the effective uterine artery blood flow. There was no statistically significant change in the hormonal profile, uterine dimensions, or endometrial thickness.

CONCLUSION(S)

Danazol therapy for 6 weeks results in a significant increase in the uterine artery impedance and hence a possible reduction in the effective uterine artery blood flow. This may explain in part its efficacy in the management of dysfunctional uterine bleeding and in the preoperative preparation of women undergoing endoscopic endometrial ablation. The exact mechanism for its action in this regard remains to be determined but appears to be independent of E2 levels. This preliminary finding may help in monitoring the treatment of dysfunctional uterine bleeding, preoperative and postoperative investigation of women undergoing endoscopic endometrial ablation, and the development of alternative treatment strategies for dysfunctional uterine bleeding in the future.

Does preoperative treatment with a gonadotropin-releasing hormone agonist improve the outcome of endometrial resection?

STUDY OBJECTIVE

To verify if more favorable long-term results of endometrial resection can be obtained with preoperative gonadotropin-releasing hormone (GnRH) agonist treatment.

DESIGN

Multicenter, randomized, controlled trial (Canadian Task Force classification I).

SETTING

Tertiary care academic department.

PATIENTS

Sixty-three premenopausal women with established menorrhagia.

INTERVENTION

Eight weeks of goserelin depot treatment before endometrial resection or immediate surgery in the early proliferative phase of the cycle.

MEASUREMENTS AND MAIN RESULTS

Variations in menstrual patterns and bleeding scores as well as overall degree of satisfaction with treatment were determined 1 year after endometrial resection. Mean +/- SD monthly pictorial blood loss-assessment chart scores in the second 6-month follow-up period were 26.9 +/- 31.6 in the goserelin group and 44.0 +/- 45.7 in the immediate surgery group (mean difference 17.1 points, 95% CI -3.0 to +37.2, p = 0.09, unpaired t test). Respective amenorrhea rates were 34% (11/32) and 20% (6/20, p = 0.26, Fisher's exact test, 95% CI of difference -8% to +37%). Overall satisfaction with treatment was 91% and 87%, respectively.

CONCLUSION

Administration of a GnRH agonist before endometrial resection is advantageous for surgery, but has a limited effect in terms of postoperative bleeding pattern and appears not to offer clear-cut long-term clinical benefit.

Biochemical hemodynamic and hematological changes during transcervical resection of the endometrium using 1.5% glycine as the irrigating solution

OBJECTIVE

To study fluid absorption during transcervical resection of the endometrium (TCRE) and its effect on the biochemical, hemodynamic and hematological alterations so that life threatening complications of fluid overload may be prevented.

METHOD

Intraoperative fluid (1.5% glycine) absorption in 46 women undergoing TCRE was studied and correlated using biochemical parameters (serum sodium, potassium, total proteins, creatinine and blood urea), hemodynamic parameters (pulse rate, blood pressure, oxygen saturation and end tidal CO2) and hematological parameters. Twenty five of these patients had received danazol (800 mg/day) for six weeks prior to TCRE.

RESULT

The mean glycine deficit during TCRE was found to be 474.45 ml, with a mean total inflow of 3802.17 ml. Amongst all of the parameters, only serum sodium levels were found to be significantly inversely correlated with the glycine deficit. No case of hyponatremia occurred below a deficit of 1000 ml. Severe hyponatremia was reported in three cases (6.4%) and all three had a glycine deficit of more than 1000 ml. No case of pulmonary edema was noted. The mean glycine deficit was significantly lower (P=0.007) and the duration of procedure significantly shorter (P=0.0009) in the patients who had received danazol. None of the patients in the danazol group had fluid absorption of more than 1000 ml.

CONCLUSION

Close monitoring of fluid inflow and outflow should be done during TCRE. Above a deficit of 1000 ml, serum sodium should be measured to detect significant hyponatremia. The use of danazol for endometrial preparation also reduces the mean amount of fluid absorbed.

Endometrial Na+, K+-ATPase pump function and vasopressin levels during hysteroscopic surgery in patients pretreated with GnRH agonist

STUDY OBJECTIVE

To investigate the effects of gonadotropin-releasing hormone (GnRH) analog pretreatment on endometrial Na+, K+-adenosine triphosphatase (ATPase) pump function and peripheral blood vasopressin levels, and their role in fluid absorption and mechanisms of hyponatremia in patients undergoing hysteroscopic endometrial ablation.

DESIGN

Prospective, randomized, placebo-controlled study (Canadian Task Force classification I).

SETTING

University-affiliated hospital.

PATIENTS

Seventeen women with dysfunctional uterine bleeding.

INTERVENTION

Nine women received a GnRH analog and eight received saline approximately 6 to 8 weeks before hysteroscopic ablation by electrosurgery.

MEASUREMENTS AND MAIN RESULTS

Both before randomization and immediately before surgery, endometrial biopsy samples were obtained and numbered consecutively without patient identification. Operative hysteroscopy was performed with glycine 1.5% mixed with 2% alcohol. The amount of irrigant and irrigant deficit; blood levels of albumin and ethanol; hematocrit and hemoglobin; changes in sodium levels; and central venous pressure were compared. The Na+, K+-ATPase pump activity was significantly increased in the GnRH analog group compared with the saline group and correlated with decreased estradiol levels (0.4 +/- 0.08 vs 0.26 +/- 0.06 micro mol/min/ml). Vasopressin levels were significantly lower in the GnRH group (3.2 +/- 0.9 vs 7.6 +/- 1.7 micro mol/L). Mean volume of irrigant used and operating time were similar in both groups. Volume deficit, decrease in protein, and hematocrit were less in GnRH than in the saline group. Blood ethanol levels, decrease in sodium, and irrigant deficit were significantly lower in GnRH group.

CONCLUSION

Pretreatment with GnRH analogs may prevent the adverse effects of estradiol on endometrial Na+, K+-ATPase and creates a protective mechanism against iatrogenic hyponatremia, which is more critical in women than men in case of absorption of irrigating fluid. Moreover, created hypoestrogenism may enhance Na+, K+-ATPase activity in brain as well as endometrium, thus decreasing women's susceptibility to hyponatremic complications and brain damage. Suppressed vasopressin levels may be protective against fluid absorption in GnRH analog-treated patients.

Postoperative granulomas of the endometrium: histological features after endometrial ablation

Postoperative granulomas of the male urogenital tract are a well-recognized phenomenon. Similar granulomas have also been described in the uterine cervix, fallopian tube, and other sites after various procedures, as well as in the endometrium after endometrial ablation procedures. Endometrial ablation is a procedure increasingly used by gynecologists to relieve symptoms associated with dysfunctional uterine bleeding. Occasionally, patients will not have a satisfactory result, and some will require subsequent hysterectomy. We describe the pathological findings in the hysterectomy specimens from 15 patients who had previously undergone endometrial ablation. Indications for subsequent hysterectomy included dysmenorrhea (7 patients), menorrhagia (7 patients), dysfunctional uterine bleeding (5 patients), and pelvic pain (4 patients). All patients had varying degrees of fibrosis of the endometrial cavity, with some endometrial cavities completely obliterated by fibrous tissue. Histological examination revealed fibrosis with varying degrees of granulomatous inflammation. The majority of the granulomas were associated with refractile brown hematoidin-like pigment, and most were also associated with uniform black pigment. In 8 cases, areas of faintly eosinophilic, homogenous, hyalinized material were present within the endometrium. Comparison is made to granulomas due to other causes, because the postoperative granulomas of the endometrium differ morphologically from granulomatous inflammation caused by other etiologies. As endometrial ablation gains popularity among gynecologists and their patients, it is likely that the practicing pathologist may encounter these sequelae with increasing frequency.

A national survey of the complications of endometrial destruction for menstrual disorders: the MISTLETOE study. Minimally Invasive Surgical Techniques--Laser, EndoThermal or Endorescetion

OBJECTIVES

To study the frequency of complications of endometrial resection and ablation for menstrual disturbances and the influence of the experience of the operators.

DESIGN

Prospective survey with additional retrospective reporting by theatre staff.

SETTING

300 National Health Service and independent hospitals in the United Kingdom (excluding Scotland).

POPULATION

10,686 women registered by 690 doctors (1-222 cases/doctor) from April 1993 to October 1994.

METHODS

Mailings were sent to relevant medical and non medical staff at every hospital to ascertain who performed the operations. These doctors were asked to complete a questionnaire detailing their previous experience. Completed patient registration forms were returned each month. Theatre contacts returned lists of cases reported in theatre registers.

MAIN OUTCOME MEASURES

Perioperative, post-operative and delayed complications by method of surgery and experience of operator.

RESULTS

Two directly related deaths were reported. Laser and rollerball ablations were associated with least operative and post-operative complications. Combined loop and rollerball diathermy was associated with a higher rate, but with fewer immediate operative complications than loop resection alone. Endometrial thinning agents were not associated with decreased complications. Fibroids were associated with increased operative haemorrhage. Early post-operative complication rates ranged from 0.77% to 1.51%. Six-week follow up in 82.5% of the women revealed few complications (1.25% to 4.58%). Increasing operative experience was associated with fewer uterine perforations in the loop resection alone group (chi 2 for trend, P < 0.001), but had no effect on operative haemorrhage in any group.

CONCLUSIONS

These procedures were used widely in 1993 to 1994 with low morbidity and mortality. The techniques may be relatively easily learned in the apprenticeship system without compromising safety. Combined diathermy resection appears safer than loop resection alone, but laser and rollerball ablation were safest.

Preventing hyponatremic encephalopathy: comparison of serum sodium and osmolality during operative hysteroscopy with 5.0% mannitol and 1.5% glycine distention media

STUDY OBJECTIVE

To determine whether isotonic 5.0% mannitol is superior to 1.5% glycine in preventing development of hyponatremic encephalopathy.

DESIGN

Prospective, comparative study (Canadian Task Force classification II=2).

SETTING

Gynecology department of a community hospital.

PATIENTS

One hundred twenty-two women undergoing operative hysteroscopy.

INTERVENTIONS

Eighteen blood serum chemical indicators analyzed preoperatively and postoperatively in 61 women undergoing operative hysteroscopy with 1. 5% glycine (group 1) were compared with those of 61 women having similar surgery with 5.0% mannitol (group 2). Fluid deficit (difference between input and output volume of distention fluid) was recorded, and differences between presurgical and postsurgical indicators of the two groups (mean difference score) were compared.

MEASUREMENTS AND MAIN RESULTS

Mean +/- SEM sodium difference scores of groups 1 and 2 were -1.73 +/- 0.42 mEq/L (range -7.00 to 2.00 mEq/L) and -5.04 +/- 1.07 mEq/L (range -36.00 to 3.00 mEq/L), respectively (p <0.01). Serum osmolality difference scores were -6. 88 +/- 1.36 mmol/L (range -13.00 to -1.00 mmol/L) and -1.87 +/- 0.35 mmol/L (range -3 to 15 mmol/L), respectively (p <0.01). Distention fluid deficits were 0.435 +/- 0.071 L (range 0-2.448 L) and 0.473 +/- 0.084 L (range 0-3.640 L), respectively (p = 0.862). Two women (3.4%) in group 1 and five (8.2%) in group 2 developed postoperative asymptomatic dilutional hyponatremia (p = 0.211), which was the only complication. Two of the five women in group 2 developed severe dilutional hyponatremia.

CONCLUSION

We found that 5.0% mannitol distention fluid produces greater postoperative dilutional hyponatremia than 1.5% glycine, but hypo-osmolality does not occur with mannitol. Its use should lessen the risk of hyponatremic encephalopathy.

Not so benign endometrial hyperplasia: endometrial cancer after endometrial ablation

The masking or development of endometrial cancer after endometrial ablation is a concern often alluded to in discussions of complications of endometrial ablation. It is necessary to look for a common factor when this complication occurs. Six cases published in peer-reviewed literature were collected to establish a link between the development of endometrial cancer and endometrial ablation. Preexisting endometrial hyperplasia seems to be the common denominator, and should be considered a contraindication to endometrial ablation until more data are collected.

Hormonal inhibition of endometrium for transcervical endometrial ablation--a prospective study with a 2-year follow-up

OBJECTIVE

To determine the best pretreatment of the endometrium prior to roller ball endometrial ablation.

STUDY DESIGN

Forty patients with recurrent hypermenorrhea underwent diagnostic hysteroscopy and dilation and curettage. They were then assigned to receive either no pretreatment or pretreatment with danazol, a GnRH-analogue, or a gestagen prior to roller ball endometrial ablation. Endometrial suppression was estimated by the surgeon at the time of the procedure, and endometrial biopsies were obtained. Patients were followed for 24 months.

RESULTS

The subjective estimation of the surgeon showed a sufficient pretreatment after danazol or a GnRH-analogue in 90% of the cases. Histological findings correlated with these findings. The highest level of amenorrhoea at 2 years of follow-up was also reached after danazol or GnRH-analogue pretreatment.

CONCLUSIONS

Danazol- or GnRH-analogue should be used for pretreatment prior to endometrial ablation using the roller ball technique.

Endometrial ablation and hysteroscopic myomectomy by electrosurgical vaporization

Electrosurgical vaporization, first performed by urologists in prostate surgery, is useful during operative hysteroscopy for endometrial ablation and myomectomy. From June 1995 through May 1996, 9 surgeons performed 44 endometrial ablations and hysteroscopic myomectomies using the vaporization electrode. Our experience with this technique thus far has been very favorable. The procedure is less expensive than laser ablation and is easier to teach than wire loop resection. It is also less tedious than wire loop resection since myoma chips that often obstruct the operator's view are eliminated. Long-term efficacy of this technique remains to be proved.

Endometrial resection and late reoperation in the treatment of menorrhagia

STUDY OBJECTIVE

To evaluate the effectiveness of transcervical resection of the endometrium and indications for late reoperation.

DESIGN

Retrospective study.

SETTING

Central hospital in northern Norway.

PATIENTS

Two hundred fifty women (age 30-59 yrs) with dysfunctional bleeding.

INTERVENTIONS

Hysteroscopic transcervical resection of the endometrium.

MEASUREMENTS AND MAIN RESULTS

Success as measured by patient satisfaction at 3-month follow-up was 97% and at 4 to 48 months was 91.6%. Mean observation time was 24 months. Twenty-one women required further surgery. Repeat resection was performed in eight women (3.2%), of whom 95% were satisfied. Thirteen women (5.2%) had a hysterectomy. Late reoperation was performed in 7 patients (2.8%) due to recurrent unacceptable vaginal bleeding and in 14 (5.6%) due to late onset of pain.

CONCLUSION

After endometrial resection, a definite subgroup (8.4%) of women developed late onset of pain or bleeding requiring reoperation.

Pre- and postoperative therapy with GnRH agonist for endometrial resection. A prospective, randomized study

BACKGROUND

To assess the value of endometrial preparation, with preoperative and pre- and postoperative GnRH agonist therapy in transcervical endometrial resection.

METHODS

Sixty women with menorrhagia were randomly divided between three groups: A: no preoperative preparation, B: goserelin 3.6 mg given as a subcutaneous implant 4-6 weeks preoperatively, and C: the same regimen as B, and repeated on the day of endometrial resection. At follow-up visits 1, 3, 6 and 12 months after operations the patients were interviewed for duration, amount and pains of menstrual periods.

RESULTS

The duration of surgery for the pretreated group (32.8 +/- 5.1 min) and the group treated postoperatively (30.9 +/- 8.9 min) were significantly shorter than that in the control group (46.4 +/- 11.5 min) (p < 0.01). The weight of endomyometrial strips was about 3 times lower for group B and C as compared to group A (p < 0.01). Three months following the procedure twenty five percent of patients in group A were amenorrheic or showed scanty bleeding as compared to 58% and 85% in group B and C (p < 0.05 and p < 0.01), respectively. At 12 months follow-up these rates were 35%, 58% and 67% respectively (A versus B: NS, A versus C: p < 0.05) and 24%, 65% and 75% after excluding larger submucosal fibroids (A versus B: p < 0.025, A versus C: p < 0.005). No statistical difference was demonstrated between group B and C. Sixty-nine percent of pretreated patients (group B + C) versus 35% of women in group A reported improved or relieved menstrual cramps (p < 0.05).

CONCLUSIONS

GnRH pretreatment facilitates endometrial resection and increases the rate of amenorrhea and scanty bleeding postoperatively. Whether supplementary postoperative therapy with GnRH agonist enhances the success rate further is uncertain.

Administration of medroxyprogesterone acetate after endomyometrial resection

STUDY OBJECTIVE

To assess the efficacy of endometrial resection for treatment of menorrhagia in women to whom no preoperative agent was given to prepare the endometrium.

DESIGN

Retrospective analysis of patients' records for all endometrial resections in which medroxyprogesterone acetate was used postoperatively.

SETTING

Hospital day surgery unit.

PATIENTS

Seventy patients with menorrhagia.

INTERVENTIONS

The women underwent transvaginal sonography, followed by hysteroscopy and endometrial biopsy. The endometrium was removed using the 27F resectoscope followed by coagulation with the rollerball. Medroxy-progesterone acetate was prescribed for 2 months after surgery.

MEASUREMENTS AND MAIN RESULTS

All women achieved a reduction in menstrual flow and 50% reported amenorrhea after endometrial resection. In only two was hysterectomy necessary due to recurrence of menorrhagia.

CONCLUSION

Preoperative endometrial preparation was unnecessary when endometrial resection was carried out for treatment of menorrhagia. However, the patients received medroxyprogesterone acetate postoperatively.

Relationship of endometrial thickness with the menstrual timing of leuprolide acetate administration for preoperative preparation for hysteroscopic surgery

STUDY OBJECTIVES

To assess the relationship of menstrual timing of administration of gonadotropin-releasing hormone (GnRH) agonist on the effectiveness of endometrial thinning and unwanted uterine bleeding.

DESIGN

Prospective observational study.

SETTING

Gynecology department of a community hospital.

PATIENTS

One hundred consecutive women in a private practice, without submucous myomas, scheduled for transcervical endomyometrial resection or ablation.

INTERVENTIONS

A GnRH agonist was administered at an unspecified time of the menstrual cycle. Transcervical hysteroscopic endomyometrial resection or ablation was performed 1 month later.

MEASUREMENTS AND MAIN RESULTS

No significant statistical differences were seen in either the effectiveness of endometrial thinning or the occurrence or severity of unwanted uterine bleeding.

CONCLUSIONS

A GnRH agonist as pretreatment for endomyometrial resection or ablation can be administered at any time during the menstrual cycle with similar efficacy. Timing of surgery can be at the mutual convenience of patient and physician.

Experience with 800 hysteroscopic endometrial ablations

STUDY OBJECTIVE

To determine the safety and efficacy of hysteroscopic endometrial ablation in women with menometrorrhagia.

DESIGN

Retrospective record review.

SETTING

A credentialing program in teaching and nonteaching hospitals.

PATIENTS

Eight hundred women who underwent endometrial ablation in 54 hospitals, with indications of abnormal uterine bleeding disrupting lifestyle, postmenopausal bleeding during hormone replacement therapy, poor surgical risk for hysterectomy, or desire to preserve the uterus.

INTERVENTIONS

Seventy percent of the patients were treated with danazol 100 to 600 mg/day for 6 to 12 weeks, 8% received gonadotropin-releasing hormone analogs, 7% received progestins, and 15% were given no preoperative treatment. Under appropriate anesthesia the cervix was dilated to 10 mm and the uterine cavity was distended with 1.5% glycine solution under gravity inflow of 80 to 100 cm water and outflow suction of 80 to 100 mm Hg pressure. Electrocoagulation with or without resection was completed using 100 and 125 W, respectively.

MEASUREMENTS AND RESULTS

At 12 months 60% of patients reported amenorrhea, 29% hypomenorrhea, 6% eumenorrhea, and 5% no change. Repeat ablation was performed in 4% of patients. An additional 2% had hysterectomy for malignancy (endometrium 2, sarcoma 1, atypical hyperplasia 1), pelvic pain (4), fibroids (4), persistent bleeding (3), and endometritis (2). The complication rate was 3.9%: false passage during cervical dilatation (6), uterine perforation (dilator 4, resectoscope 2, Laminaria 1), fluid absorption greater than 1500 ml (8), minor bleeding (5), endomyometritis (4), and intrauterine pregnancy (1).

CONCLUSIONS

Hysteroscopic endometrial ablation is a safe and effective treatment for women with menometrorrhagia.

The degree of fluid absorption during hysteroscopic surgery in patients pretreated with goserelin

STUDY OBJECTIVE

To assess the effects of pretreatment with the gonadotropin-releasing hormone analog goserelin on fluid absorption in patients undergoing hysteroscopic endometrial ablation.

DESIGN

Prospective, randomized, placebo-controlled study.

SETTING

A university-based clinic.

PATIENTS

Thirteen women with dysfunctional uterine bleeding who were scheduled for electrosurgical hysteroscopic ablation.

INTERVENTIONS

Seven women were randomized to receive luteal phase goserelin 3.75 mg and six saline in the menstrual cycle approximately 10 weeks before surgery. Operative hysteroscopy was carried out with glycine 1.5% mixed with 2% alcohol medium under constant pressure as an irrigant. The amount of irrigant used, irrigant deficit, blood levels of albumin and ethanol, hematocrit, hemoglobin, changes in sodium levels, and central venous pressure were compared between the groups.

MEASUREMENTS AND MAIN RESULTS

All of the patients had an unsuccessful course of medical therapy for at least 3 months and a normal endometrial biopsy. The age, weight, and uterine size were similar between the groups. The mean volume of irrigant used and operating time were similar in both groups (4.18 +/- 0.2 vs 4.5 +/- 0.5 L, and 33.7 +/- 1.5 vs 37 +/- 2.1 min). Although operating time, volume deficit, decrease in protein level, and hematocrit were less in the goserelin than in the saline group, the differences were not statistically significant (p >0.05). The ethanol levels in blood, decrease in Na+, and irrigant deficit were significantly lower in the goserelin than in the saline group (17.4 +/- 3.8 vs 25.3 +/- 4.2 mg/ml, 6.7 +/- 1.2 vs 9.1 +/- 0.9 mEq/L, and 0.49 +/- 0.08 vs 0.66 +/- 0.05 L, respectively; p <0.05).

CONCLUSION

Based on these results we conclude that in women undergoing hysteroscopic endometrial ablation, pretreatment with goserelin may decrease the absorption of hysteroscopic medium, prevent fluid overload, and improve the outcome possibly by causing hypovascularity and decreased endometrial growth.

Endometrial resection for the treatment of menorrhagia

BACKGROUND

Endometrial resection is an alternative to hysterectomy in the treatment of women with menorrhagia, but it may not control the condition. We sought to evaluate the effectiveness of such resection.

METHODS

We followed 525 consecutive women (mean age at initial surgery, 42 years) for up to five years after endometrial resection. The women were examined 6 to 12 weeks after the operation and were then sent yearly questionnaires seeking information about their condition. The mean duration of follow-up was 31 months. Thirty-seven women (86 percent of the 43 women available for five years of follow-up) were followed for the entire period.

RESULTS

Endometrial resection was completed successfully in 95 percent of the women, with operative complications in 6 percent. Forty-eight women underwent subsequent resection. The yearly questionnaires indicated that 85 to 100 percent of the women (depending on the year of follow-up) had adequately controlled menorrhagia, 26 to 40 percent had amenorrhea, 71 to 80 percent reported either a lessening of menstrual pain or no pain, and 79 to 87 percent were satisfied with the results of their surgery. No further surgery was needed by 80 percent of the women, and only 9 percent underwent hysterectomy during the five years of follow-up, with 98 percent of those operations being performed in the first three postoperative years.

CONCLUSIONS

Endometrial resection is an effective alternative to hysterectomy in women with menorrhagia.

Treatment with a gonadotrophin releasing hormone agonist before endometrial resection: a multicentre, randomised controlled trial

OBJECTIVES

To ascertain whether treatment with a gonadotrophin releasing hormone agonist before endometrial resection reduces absorption of distension fluid and operating time and facilitates the procedure.

DESIGN

A multicentre, prospective, randomised controlled study.

PARTICIPANTS

Seventy-one premenopausal women with established menorrhagia.

INTERVENTIONS

Eight weeks of goserelin depot treatment before endometrial resection of immediate surgery in the early proliferative phase of the cycle.

MAIN OUTCOME MEASURES

Irrigation fluid deficit, operating time and degree or difficulty of the procedure.

RESULTS

After randomisation eight women withdrew from the study, leaving 33 women in the goserelin arm and 30 in the immediate surgery arm. Mean (SD) operating time was 15.1 (9.0) min in the goserelin group versus 16.9 (9.5) min in the controls; mean difference + 1.8 min, 95% CI, -2.9 to + 6.4. Mean (SD) distension medium deficit was, respectively, 422 (287) ml versus 564 (291 ml); mean difference + 142 ml, 95% CI -4 to + 288. The goserelin effect was restricted to the 29 women with adenomyosis as the mean (SD) fluid deficit was considerably less in the 19 treated women than in the 10 controls (299 (206) ml versus 597 (135) ml; mean difference + 298 ml, 95% CI + 149 to + 447). The surgeons classified the intraoperative difficulties as none in 6, minimal in 20, moderate in 7, and severe in no cases in the goserelin group; corresponding figures in the group without pretreatment were 2, 14, 13, and 1.

CONCLUSIONS

Goserelin administration before endometrial resection may reduce absorption of fluid at surgery in women with adenomyosis and may facilitate intrauterine operating conditions.

A comparison of goserelin and danazol as endometrial thinning agents prior to endometrial laser ablation

OBJECTIVE

To compare the effectiveness of goserelin and danazol prior to endometrial laser ablation and assess different dosage regimens.

DESIGN

A prospective open randomised trial.

SETTING

Specialist unit in minimal access gynaecological surgery in a district general hospital.

PARTICIPANTS

One hundred and sixty premenopausal women with dysfunctional uterine bleeding.

INTERVENTIONS

Randomisation into four groups receiving either one or two injections of goserelin acetate (3.6 mg subcutaneously) or 28 or 56 days of danazol (four 200 mg tablets daily), followed by endometrial laser ablation.

MAIN OUTCOME MEASURES

Endometrial thickness pretreatment and, immediately prior to endometrial laser ablation, assessed by vaginal ultrasound and full thickness endometrial biopsy; appearance of the endometrium at surgery; duration of the operation; the amount of fluid absorbed during surgery; and the clinical outcome at 24 weeks after surgery.

RESULTS

The two drugs were equally effective in thinning the endometrium. Compared with danazol, goserelin was better tolerated and resulted in a more satisfactory endometrial appearance at hysteroscopy, a greater reduction in cavity length (0.5 cm compared with 0.3 cm, P = 0.002), a shorter operation (16.4 min compared with 21.6 min, P < 0.001), less fluid absorption (0 ml compared with 200 ml, P = 0.001), and a higher rate of amenorrhoea or oligoamenorrhoea (77% compared with 54%, P < 0.001) at the six month check. The administration of goserelin for 8 weeks compared with 4 weeks produced greater thinning of the endometrium on ultrasound and on histological examination, a greater reduction in cavity length on ultrasound and an increase in reported vasomotor symptoms. In both treatment regimens, 95% of women reported a satisfactory reduction in menstrual flow at the six month check.

CONCLUSIONS

Goserelin appears to be more effective and better tolerated than danazol for treatment prior to endometrial laser ablation. Eight weeks treatment with goserelin resulted in better operating conditions and more vasomotor side effect, compared with four weeks treatment, although there was no difference in clinical outcome.

Endometrial electrosurgical resection by hysteroscopy in 32 menorrhagic patients: endometrial preparation with a GnRH agonist may have some effect on results

Our objective was to evaluate the effect of endometrial thinning by GnRH agonists on the results of hysteroscopic endometrial electrosurgical resection. In a prospective study, 32 women were treated with the GnRH agonist goserelin (Zoladex) before hysteroscopic endometrial resection. Endometrial thickness was measured before and after GnRH-a therapy by ultrasound. Short-term results in diminished vaginal blood loss and patient satisfaction were registered. The mean endometrial thickness (ET) before GnRH-a is 3.7 mm and after GnRH-a is 1.9 mm. In 24 cases, ET was reduced by a mean of 2.6 mm, in 1 case, no change was seen, and in 7 cases, ET increased by a mean 1.1 mm. The mean thickness rate (TR = ET before and after GnRH) is 2.7 (range 0.3-11). Fluid resorption during hysteroscopic surgery does not relate to ET or TR. Although the ET after GnRH-a therapy is not related to success or failure of the endometrial resection, there is some evidence that the TR is, probably expressing a more active state of the endometrium. Endometrial thinning by GnRH-a may have an effect on the results of hysteroscopic endometrial resection. In light of the present study and the literature, there seems to be no justification for abandoning preparation of the endometrium before hysteroscopic surgery.

A mathematical model for light dosimetry in photodynamic destruction of human endometrium

We are involved in the development of photodynamic therapy (PDT) as a minimally invasive method for treating dysfunctional uterine bleeding, one of the primary clinical indications for hysterectomy. In this paper, we analyse light propagation through the uterus in order to specify the requirements for a light delivery system capable of effectively performing endometrial PDT. Our approach involves developing an analytical model based on diffusion theory to predict optical fluence rate distributions when cylindrical and spherical optical applicators are placed in the uterine cavity. We apply the results of our model calculations to estimate the thermal effects of optical irradiation and the effective photodynamic optical dose. Theoretical fluence rate calculations are compared to fluence rate measurements made in fresh, surgically removed human uteri. Our results show that a trifurcated cylindrical optical applicator inserted into the human uterus can provide a light dose that is sufficient to cause photodynamic destruction of the entire endometrium. When the optical power per unit length of each cylindrical applicator is 100 mW cm-1 (at 630 nm), a fluence rate of 40 mW cm-2 is delivered to the boundary layer between the endometrium and the myometrium (a depth of about 4-6 mm). The optical fluence delivered to the boundary layer after 20 min of exposure is 50 J cm-2, a level that is generally accepted to cause tissue damage throughout the endometrium in most patients.

Transcervical endometrial resection

STUDY OBJECTIVES

To determine the safety and efficacy of endometrial resection, and to provide an indicator of the operative problems and treatment outcomes.

DESIGN

Prospective study.

SETTING

Academic practice tertiary care setting.

PATIENTS

One hundred twenty-six consecutive women undergoing endometrial resection because of menorrhagia, who wished to retain their uterus.

INTERVENTION

Hysteroscopic endometrial resection performed as a day procedure.

MEASUREMENTS AND MAIN RESULTS

In 126 women, 2 cases of uterine perforation were readily identified on the operating monitor screen; they had no serious sequelae. Three patients had heavy uterine bleeding, which was controlled by intrauterine tamponade. No women had other serious complications.

CONCLUSION

Hysteroscopic endometrial resection is a safe, successful, and cost-effective treatment of menorrhagia.

Abnormal uterine bleeding

Physicians who care for female patients cannot avoid the frequent complaint of abnormal uterine bleeding. Knowledge of the disorders that cause this problem can prevent serious consequences in many patients and improve the quality of life for many others. The availability of noninvasive and minimally invasive diagnostic studies and minimally invasive surgical treatment has revolutionized management of abnormal uterine bleeding. Similar to any other disorder, the extent to which a physician manages abnormal uterine bleeding depends on his or her own level of comfort. When limitations of either diagnostic or therapeutic capability are encountered, consultation and referral should be used to the best interest of patients.